Status: Recruiting
A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep, as compared with placebo, in the treatment of moderate or severe of migraine.
Participants needed: 1,500
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Kallyope Inc.Updated: Oct 7, 2026Locations: 72
Eligibility criteria
A minimum of 12 months of spontaneous amenorrhea or [+12]
Is a female who is pregnant, breast-feeding, or intends to become pregnant durin... [+34]